Cargando…
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy
BACKGROUND: People living with multiple sclerosis (MS) and other disorders treated with immunomodulatory therapies remain concerned about suboptimal responses to coronavirus disease 2019 (COVID-19) vaccines. Important questions persist regarding immunological response to third vaccines, particularly...
Autores principales: | Katz Sand, Ilana, Gnjatic, Sacha, Krammer, Florian, Tuballes, Kevin, Carreño, Juan Manuel, Satyanarayan, Sammita, Filomena, Susan, Staker, Erin, Tcheou, Johnstone, Miller, Aaron, Fabian, Michelle, Safi, Neha, Nichols, Jamie, Patel, Jasmin, Krieger, Stephen, Tankou, Stephanie, Horng, Sam, Klineova, Sylvia, Beck, Erin, Merad, Miriam, Lublin, Fred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794520/ https://www.ncbi.nlm.nih.gov/pubmed/36628884 http://dx.doi.org/10.1016/j.msard.2022.104486 |
Ejemplares similares
-
Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis
por: Satyanarayan, Sammita, et al.
Publicado: (2022) -
Sleep disturbance and memory dysfunction in early multiple sclerosis
por: Sumowski, James F., et al.
Publicado: (2021) -
Objective and subjective measures of dalfampridine efficacy in clinical practice
por: Klineova, Sylvia, et al.
Publicado: (2018) -
510. Elevated IL-1β level as a predictor of inflammation and death in COVID-19
por: Swartz, Talia H, et al.
Publicado: (2020) -
Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections
por: Singh, Gagandeep, et al.
Publicado: (2023)